Overview: NGS Leber Congenital Amaurosis Sequencing TestIntroduction: The NGS Leber Congenital Amaurosis Sequencing Test sequences genes to diagnose Leber congenital amaurosis (LCA), causing severe vision loss. Following 2023 AAO guidelines, it uses PCR for high specificity, supporting vision screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected LCA.
Other Names: LCA Assay, CEP290/GUCY2D Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: LCA sequencing began in the 1990s with retinal dystrophy research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose LCA, guides treatment, and evaluates patients with severe vision loss.
Test Parameters: 1. LCA Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of severe vision loss, nystagmus, or LCA symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document severe vision loss, nystagmus, photophobia, or family history of LCA. Include current medications, especially vision-related treatments.
Consent: Written consent required, detailing the tests purpose, LCA implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze LCA genes (e.g., CEP290, GUCY2D). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for LCA diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm LCA, guiding gene therapy or genetic counseling. Negative results may require broader retinal panels.
Specialist Consultation: Consult an ophthalmologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Electroretinography (ERG), retinal imaging, or visual acuity testing to confirm LCA diagnosis.
Test Limitations: Not all LCA cases are detected; clinical correlation is needed. Sample quality affects sensitivity.
References: AAO LCA Guidelines, 2023; Ophthalmology, den Hollander AI, 2022.
